Metoprolol for Heart Failure

This trial tests how the medication metoprolol works for people with Heart Failure with Reduced Ejection Fraction (HFrEF). Researchers aim to determine if genetics influence the response to metoprolol. Participants will provide genetic information to assess their response to the medication. This trial suits those with HFrEF who haven't recently used a beta-blocker. As a Phase 4 trial, metoprolol is already FDA-approved and proven effective, and this research seeks to understand how it benefits more patients.

The trial does not specify if you need to stop taking your current medications, but you must not have taken a beta-blocker in the past 3 to 6 months. You should also be on a stable dose of certain heart medications like ACE inhibitors or diuretics for a few weeks before joining.

Research has shown that metoprolol succinate is generally safe for people with heart failure. One study found it reduced the risk of hospital visits for worsening heart failure by 19% and improved symptoms. Another study found it lowered the overall death rate by 34% in heart failure patients.

When started carefully, most people with mild to moderate heart failure can take metoprolol safely. The FDA has also approved it for treating other heart conditions, indicating it is usually well-tolerated.

Unlike the standard heart failure treatments, which often include ACE inhibitors, ARBs, or diuretics, metoprolol succinate is a beta-blocker that specifically targets beta-adrenergic receptors in the heart. This helps to reduce heart rate and improve heart function over time. Researchers are excited about metoprolol succinate because it has the potential to offer more precise control over heart failure symptoms and may improve the overall outcomes for patients by specifically moderating the effects of adrenaline on the heart. Additionally, its once-daily dosing makes it convenient for patients to adhere to their treatment regimen.

Research has shown that metoprolol succinate, the treatment under study in this trial, effectively treats heart failure with reduced ejection fraction (HFrEF). Studies indicate it helps people live longer without heart-related events compared to other forms of metoprolol. Specifically, it reduces the likelihood of hospitalization for worsening heart failure by 19%. Importantly, metoprolol has reduced the overall risk of death by 34% in heart failure patients. This evidence supports its effectiveness in managing heart failure symptoms and improving patient outcomes.¹²⁴⁶⁷